Search
5. Infections

The products in this chapter have not been given a colour classification as the CDDFT antibiotic formulary has a different traffic light system which details the level of restriction within the trust.

Guidelines

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Drug allergy: diagnosis and management of drug allergy in adults, children and young people (CG183)

NICE CG191: Pneumonia: Diagnosis and management of community- and hospital-acquired pneumonia in adults

NICE NG15: Antimicrobial Stewardship – systems and processes for effective antimicrobial medicine use

NICE NG33: Tuberculosis

NICE NG63: Antimicrobial stewardship: changing risk-related behaviours in the general population

CD&D APC Patient Decision Aids Resource available at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington/

CD&D APC “Do Not Prescribe List” and “Grey List – drugs prescribed under limited circumstances” available at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington/

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Benzylpenicillin
BNF | BNFC | SPC

600mg Injection

Phenoxymethylpenicillin (Penicillin V)
BNF | BNFC | SPC

250mg tablets

125mg in 5ml and 250mg in 5ml oral solutions

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Flucloxacillin
BNF | BNFC | SPC

250mg & 500mg capsules

125mg/5ml and 250mg/5ml oral solutions

 

Flucloxacillin Injection
BNF | BNFC | SPC

250mg, 500mg & 1g injections

Temocillin
BNF | BNFC | SPC

1g injection

Restricted on the advice of a Consultant Microbiologist.

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Amoxicillin
BNF | BNFC | SPC

250mg & 500mg capsules

3g sachets

125mg/5ml & 250mg/5ml sugar free syrups

 

Amoxicillin Injection
BNF | BNFC | SPC

250mg, 500mg & 1g injections

Co-amoxiclav
BNF | BNFC | SPC

Amoxicillin with clavulanic acid:
250/125 & 500/125 tablets
250/125 dispersible tablets
125/31 & 250/62 sugar-free suspensions
400/57 sugar-free suspension (Augmentin Duo®)
(quantities are indicated in the form co-Amoxiclav x/y where x
= mg amoxicillin and y = mg clavulanic acid)

Avoid broad spectrum antibiotics when narrow spectrum antibiotics remain effective, as they increase risk of Clostridium difficile, MRSA and resistant organisms.

Co-amoxiclav Injection
BNF | BNFC | SPC

500/100 (600mg) & 1,000/200 (1.2g) injections

(quantities are indicated in the form co-Amoxiclav x/y where x
= mg amoxicillin and y = mg clavulanic acid)

Avoid broad spectrum antibiotics when narrow spectrum antibiotics remain effective, as they increase risk of Clostridium difficile, MRSA and resistant organisms.

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Piperacillin with Tazobactam (Tazocin)
BNF | BNFC | SPC

2.25g & 4.5g injections containing piperacillin 2g & tazobactam 250mg/2.25g vial & piperacillin 4g & tazobactam 500mg/4.5g vial

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Pivmecillinam
BNF | BNFC | SPC

200mg tablets

Cephalosporins are associated with an increased risk of causing Clostridium difficile infection especially in the elderly and therefore should only be used when no reasonable alternative is available.

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Cefalexin
BNF | BNFC | SPC

250mg & 500mg capsules

Cefixime
BNF | BNFC | SPC

200mg tablets
100mg in 5ml paediatric suspension

See indications in CDDFT Antibiotic Formulary.

Cefotaxime
BNF | BNFC | SPC

500mg, 1g & 2g injections

Cefotaxime is reserved for use in neonates or those in whom ceftriaxone is contra-indicated.

Ceftazidime
BNF | BNFC | SPC

250mg, 500mg, 1g & 2g injections

Treatment of Pseudomonas infections or infections caused by proven resistant Gram-negative bacteria.

Ceftriaxone
BNF | BNFC | SPC

250mg, 1g & 2g injections

Treatment of bacterial meningitis or meningococcal or Haemophilus influenzae(b) septicaemia.

Cefuroxime
BNF | BNFC | SPC

250mg tablets

125mg/5ml oral suspension

Cefuroxime should only be used as in accordance with Antibiotic Formulary

Cefuroxime Injection
BNF | BNFC | SPC

250mg, 750mg & 1.5g injections

Cefuroxime should only be used as in accordance with Antibiotic Formulary

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Aztreonam
BNF | BNFC | SPC

500mg, 1g & 2g injections

Ertapenem
BNF | BNFC | SPC

1g injection

To be used on the advice of a Consultant Microbiologist for the management of resistant Gram-negative infections.

Meropenem
BNF | BNFC | SPC

500mg & 1g injections

For the treatment of Necrotising fasciitis or severe necrotising pancreatitis otherwise to be used only on the advice of a Consultant Microbiologist.

Aztrenonam Lysine (inhalation)
BNF | BNFC | SPC

75mg powder for inhalation

Approved in line with NHS England specialised commissioning criteria for the treatment of chronic pulmonary Pseudomona aeruginosa infection in patients with cystic fibrosis.

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Demeclocycline
BNF | BNFC | SPC

150mg capsules

For the treatment of inappropriate antidiuretic hormone secretion –
treatment is initiated by specialists only.

Doxycycline
BNF | BNFC | SPC

50mg & 100mg capsules; 100mg dispersible tablets

Lymecycline
BNF | BNFC | SPC

408mg capsules (= tetracycline 300mg)

Minocycline
BNF | BNFC | SPC
Oxytetracycline
BNF | BNFC | SPC

250mg tablets

Tigecycline
BNF | BNFC | SPC

50mg injection

To be used on the advice of a Consultant Microbiologist only or as recommended within the Antibiotic Formulary.

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Amikacin
BNF | BNFC | SPC

100mg in 2ml & 500mg in 2ml injections

Gentamicin
BNF | BNFC | SPC

80mg in 2ml & 20mg in 2ml injections

 

Gentamicin (Nebulised)
BNF | BNFC | SPC

Approved for the long term therapy in non-cystic fibrosis bronchiectasis as per Antibiotic Formulary

 

Neomycin
BNF | BNFC | SPC

500mg tablets

Tobramycin
BNF | BNFC | SPC

80mg in 2ml & 240mg in 6ml injections

Resistant infections on the advice of a Consultant Microbiologist

300mg in 4ml (Bramitob®) nebuliser solution - only for long-term 2nd line use in the management of chronic
pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis
(CF) patients
300mg in 5ml (Tobi®) - only to be used in existing patients as it is cheaper to use Bramitob.
TOBI Podhaler – 28mg capsule plus podhaler - approved for CF patients in line with NICE

Commissioner: NHS England - NICE TA276, Policy - A01/PS/a

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Azithromycin
BNF | BNFC | SPC

250mg capsules & tablets
200mg in 5ml suspension

Azithromycin Injection
BNF | BNFC | SPC

500mg powder vial for infusion

Clarithromycin
BNF | BNFC | SPC

250mg & 500mg tablets
125mg in 5ml & 250mg in 5ml suspensions

Clarithromycin Injection
BNF | BNFC | SPC

500mg injection

Erythromycin
BNF | BNFC | SPC

250mg e/c tablets
125mg, 250mg & 500mg in 5ml syrups

Erythromycin Injection
BNF | BNFC | SPC

1g intravenous injection (as lactobionate)

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

 

Clindamycin
BNF | BNFC | SPC

150mg capsules
75mg in 5ml suspension u

Clindamycin Injection
BNF | BNFC | SPC

300mg in 2ml & 600mg in 4ml injections

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Chloramphenicol
BNF | BNFC | SPC

250mg capsules
1g injection

Resistant infections on the advice of a Consultant Microbiologist.

Colistimethate Sodium - nebulised for CF patients
BNF | BNFC | SPC

1,000,000 & 2,000,000 unit injections (Colomycin)

1,000,000 unit nebuliser solution (Promixin)

Colistimethate Sodium - Nebulised for non-CF patients
BNF | BNFC | SPC

1,000,000 & 2,000,000 unit injections (Colomycin)

Unlicensed indication.

Colistimethate Sodium Injection
BNF | BNFC | SPC

1,000,000 & 2,000,000 unit injections

Colobreathe
BNF | BNFC | SPC

Colobreathe – 125mg capsule plus Turbospin inhaler – approved for CF patients in line with NICE

To be used on Specialist Respiratory Advice

Commissioner: NHS England - NICE TA276, Policy - A01/PS/a

MHRA Drug Safety Update (Nov’ 2014): risk of capsule breakage from inhaler device

Daptomycin
BNF | BNFC | SPC

350mg injection & 500mg injection

To be used on the advice of a Consultant Microbiologist for the management of resistant Gram-positive infections or as recommended within the Antibiotic Formulary.

Fidaxomicin▼
BNF | BNFC | SPC

200mg tablets

To be used for the treatment of Clostridium difficile on the advice of a Consultant Microbiologist.

Fosfomycin
BNF | BNFC | SPC

3g sachets

To be used on the advice of a Consultant Microbiologist for the management of resistant Gram-negative infections.

Fosfomycin Injection
BNF | BNFC | SPC

2g, 5mg powdered vials for infusion

Fusidic acid & salts
BNF | BNFC | SPC

250mg film coated tablets
250mg in 5ml suspension (Fusidic Acid) - equivalent in therapeutic effect to 175mg sodium fusidate

Linezolid
BNF | BNFC | SPC

600mg tablets
100mg in 5ml suspension


To be used on the advice of a Consultant Microbiologist for resistant Gram-positive infections.
Treated as a Hospital only drug by the manufacturer and is not available via a GP, i.e. treatment can only be started by a hospital specialist and responsibility remains with the specialist during the treatment period.
Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments. Patients should be warned to report any visual symptoms promptly (see BNF for CSM warning).
See Appendix 8 CDDFT antibiotic guidelines: Linezolid Information Leaflet which gives information for the prescriber and the patient on side effects and how the drug will be supplied and monitored when given to non admitted patients. A copy of the leaflet must be given to the patient on discharge from the hospital.

Linezolid Infusion
BNF | BNFC | SPC

600mg in 300ml IV infusion

Rifampicin
BNF | BNFC | SPC

150mg & 300mg capsules
100mg in 5ml syrup

Rifampicin Injection
BNF | BNFC | SPC

600mg vials for IV infusion

Rifaximin
BNF | BNFC | SPC

550mg tablets

Rifaximin (Targaxan): Hepatic Encephalopathy NICE TA337

Teicoplanin▼
BNF | BNFC | SPC

200mg & 400mg injections

Drug protocol: teicoplanin loading dose (CDDFT intranet access only)

Vancomycin
BNF | BNFC | SPC

125mg capsules
500mg injection (when used orally)

Vancomycin Injection
BNF | BNFC | SPC

500mg injection

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Trimethoprim
BNF | BNFC | SPC

100mg & 200mg tablets
50mg in 5ml suspension

Co-trimoxazole
BNF | BNFC | SPC

(Sulphamethoxazole 5 parts & trimethoprim 1 part)
480 mg tablets (plain or dispersible)
960mg tablets
240mg in 5ml & 480mg in 5ml suspensions

Co-trimoxazole Injection
BNF | BNFC | SPC

480mg in 5ml ampoules for IV infusion

Reserved for the treatment of TB.

Ethambutol
BNF | BNFC | SPC

100mg & 400mg tablets

Isoniazid
BNF | BNFC | SPC

50mg & 100mg tablets
50mg in 5ml elixir u

Isoniazid Injection
BNF | BNFC | SPC

50mg in 2ml injection

Pyrazinamide
BNF | BNFC | SPC

500mg tablets u
- licensed formulation discontinued, consider using Rifater where appropriate

Rifabutin
BNF | BNFC | SPC

150mg capsules

Rifampicin
BNF | BNFC | SPC

150mg & 300mg capsules
100mg in 5ml syrup

Rifampicin and Isoniazid
BNF | BNFC | SPC

Rifinah 150 tablets – rifampicin 150mg + isoniazid 100mg
Rifinah 300 tablets – rifampicin 300mg + isoniazid 150mg

Rifampicin Injection
BNF | BNFC | SPC

600mg injection (for IV infusion)

Rifater
BNF | BNFC | SPC

Tablets - rifampicin 120mg, isoniazid 50mg & pyrazinamide
300mg

Voractiv
BNF | BNFC | SPC

Isoniazid 75mg, Rifampicin 150mg, Ethambutol 275mg & Pyrazinamide 400mg tablets

Dapsone
BNF | BNFC | SPC

50mg & 100mg tablets
– used in the treatment of leprosy and some skin conditions (e.g. dermatitis herpetiformis, pemphigoid on the advice of dermatologists)

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Metronidazole
BNF | BNFC | SPC

200mg & 400mg tablets
200mg in 5ml suspension
500mg & 1g suppositories

Metronidazole Infusion
BNF | BNFC | SPC

500mg in 100ml IV infusion

Quinolone antibiotics are associated with an increased risk of Clostridium difficile infection, only to be used if no alternative.

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Ciprofloxacin
BNF | BNFC | SPC

250mg, 500mg & 750mg tablets
250mg in 5ml suspension

Ciprofloxacin Infusion
BNF | BNFC | SPC

100mg & 200mg, 400mg intravenous infusions

Levofloxacin Infusion
BNF | BNFC | SPC

500mg in 100ml intravenous infusion

Levofloxacin▼
BNF | BNFC | SPC

250mg & 500mg tablets

Moxifloxacin
BNF | BNFC | SPC

400mg tablets

Moxifloxacin Infusion
BNF | BNFC | SPC

400mg intravenous infusion

Ofloxacin
BNF | BNFC | SPC

200mg & 400mg tablets

Ofloxacin Infusion
BNF | BNFC | SPC

200mg in 100ml intravenous infusion

Antibiotics should be prescribed according to the following local guidelines:

Management of infection guidance for primary care

CDDFT antibiotic formulary  (accessible via CDDFT intranet only)

TEWV Antibiotic Guidance

Nitrofurantoin
BNF | BNFC | SPC

50mg & 100mg tablets

25mg/5ml sugar-free suspension

Metheneamine
BNF | BNFC | SPC

1g tablets

Amphotericin
BNF | BNFC | SPC

50mg injection (Fungizone®)
50mg liposomal injection (Abelcet®)

Andidulafungin
BNF | BNFC | SPC

100mg injection

To be used on the advice of a Consultant Microbiologist only for resistant Candida infections.

Caspofungin
BNF | BNFC | SPC

50mg & 70mg injections

Only to be used on the advice of a Consultant Microbiologist.
Commissioner: NHS England

Fluconazole
BNF | BNFC | SPC

50mg, 150mg & 200mg capsules
50mg in 5ml & 200mg in 5ml suspensions

Fluconazole Injection
BNF | BNFC | SPC

50mg in 25ml & 200mg in 100ml IV infusions

Itraconazole
BNF | BNFC | SPC

100mg capsules
50mg in 5ml oral solution

Itraconazole Injection
BNF | BNFC | SPC

250mg in 25ml injection for IV infusion

Ketoconazole (oral)
BNF | BNFC | SPC

See Letter Sent to Healthcare Professionals (March 2015) - Ketoconazole HRA: information about the risk of hepatotoxicity – sent by HRA Pharma on 24 March 2015

Nystatin
BNF | BNFC | SPC

100,000 units/ml suspension

Terbinafine
BNF | BNFC | SPC

250mg tablets

Voriconazole
BNF | BNFC | SPC

50mg & 200mg capsules
200mg vials for IV infusion

Voriconazole - MHRA Safety Alert (May 2014): reminder of liver toxicity, phototoxicity and squamous cell carcinoma

Only to be used on the advice of a Consultant Microbiologist.

Commissioner: NHS England

MHRA Drug Safety Update (Dec 2015): Antiretroviral medicines: updated advice on body-fat changes and lactic acidosis

Abacavir
BNF | BNFC | SPC

300mg tablets
100mg in 5ml (20mg per ml) sugar-free oral solution

Didanosine
BNF | BNFC | SPC

100mg & 200mg tablets; 250mg & 400mg e/c caps

Abacavir & Lamivudine (Kivexa®)
BNF | BNFC | SPC

600mg abacavir/600mg lamivudine tablets

Lamivudine
BNF | BNFC | SPC

150mg & 300mg tablets (treatment of HIV)
50mg in 5ml oral solution (HIV)

Tenofovir
BNF | BNFC | SPC

245mg tablets

Zidovudine
BNF | BNFC | SPC

100mg & 250mg capsules
50mg in 5ml sugar-free syrup
200mg in 20ml (10mg/ml) concentrate for IV infusion

Atazanavir
BNF | BNFC | SPC

150mg,200mg & 300mg capsules

Darunavir
BNF | BNFC | SPC

300mg, 400mg, 600mg & 800mg tablets

Lopinavir & Ritonavir (Kaletra®)
BNF | BNFC | SPC

100mg lopinavir/25mg ritonavir and 200mg lopinavir/50mg ritonavir tablets
400mg lopinavir/100mg ritonavir in 5ml oral solution

Ritonavir
BNF | BNFC | SPC

100mg capsules

MHRA Drug Safety Update (Dec 2016): Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects

Efavirenz
BNF | BNFC | SPC

50mg, 100mg & 200mg capsules

Etravirine
BNF | BNFC | SPC

100mg tablets & 200mg tablets

Nevirapine
BNF | BNFC | SPC

200mg tablets, 50mg in 5ml suspension

Maraviroc
BNF | BNFC | SPC

150mg & 300mg tablets

For use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines

Raltegravir
BNF | BNFC | SPC

400mg tablets

For use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.

Altripla
BNF | BNFC | SPC

Tablets containing efavirenz 600 mg, emtricitabine 200 mg
& tenofovir disoproxil (as fumarate) 245 mg

 

Combivir
BNF | BNFC | SPC

Tablets containing lamivudine 150mg & zidovudine 300mg

Trizivir
BNF | BNFC | SPC

Tablets containing abacavir 300mg, lamivudine 150mg & zidovudine 300mg

Truvada
BNF | BNFC | SPC

Tablets containing 200mg of emtricitabine and 245mg of tenofovir disoproxil (equivalent to 300mg of tenofovir disoproxil fumarate or 136mg of tenofovir)

Stribild▼
BNF | BNFC | SPC

Tablets containing Elvitegravir with Cobicistat, Emtricitabine and Tenofovir

Commissioner: NHS England - Policy - B06/PS/a

Rezolsta
BNF | BNFC | SPC

Tablets containing 800mg of atazanavir and 150mg of cobicistat

Evotaz
BNF | BNFC | SPC

Tablets containing 800mg of darunavir and 150mg of cobicistat

Aciclovir
BNF | BNFC | SPC

200mg, 400mg & 800mg tablets/dispersible tablets
200mg in 5ml suspension

Aciclovir Injection
BNF | BNFC | SPC

250mg & 500mg IV infusions

Valaciclovir
BNF | BNFC | SPC

500mg tablets

Valganciclovir
BNF | BNFC | SPC

450mg tablets

250mg in 5ml oral solution

Commissioner: NHS England

Lamivudine
BNF | BNFC | SPC

100mg tablets
25mg in 5ml oral solution

For use in treating Hepatitis B in accordance with NICE guidelines

Commissioner: NHS England - NICE TA153

Entecavir
BNF | BNFC | SPC

500 microgram & 1mg tablets

For use in treating Hepatitis B in accordance with NICE guidelines

Commissioner: NHS England - NICE TA153

Tenofovir
BNF | BNFC | SPC

245mg tablets

For use in the treatment of chronic hepatitis B. Preferred treatment for many patients and may be used in combination with lamivudine NICE TA173

MHRA Drug Safety Update (Jan 2017): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR

MHRA Drug Safety Update (Jan 2017): Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation

Boceprevir
BNF | BNFC | SPC

200mg capsules

Commissioner: NHS England - NICE TA253

MHRA Drug Safety Update (Nov’ 2014): baseline predictive factors for sepsis, worsening liver function, and mortality

Telaprevir▼
BNF | BNFC | SPC

375mg tablets

Commissioner: NHS England - NICE TA252

MHRA Drug Safety Update (Nov’ 2014): baseline predictive factors for sepsis, worsening liver function, and mortality

Simeprevir▼
BNF | BNFC | SPC

150mg capsules

Commissioner: NHS England - NICE TA331

See MHRA Drug Safety Update (Aug 2015) - Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone

Simeprevir (1)▼
BNF | BNFC | SPC

NICE TA361 - Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal)

Ribavirin
BNF | BNFC | SPC

200mg tablets and capsules

Commissioner: NHS England - NICE TA75, NICE TA106, NICE TA200

Used with pegylated interferon in the treatment of Hepatitis C NICE TA300

Peginterferon alfa
BNF | BNFC | SPC

Commissioner: NHS England - NICE TA200

Used with pegylated interferon in the treatment of Hepatitis C NICE TA300

Sofosbuvir▼
BNF | BNFC | SPC

400mg film coated tablets

Commissioner: NHS England - NICE TA330

See MHRA Drug Safety Update (May 2015) - Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone

See MHRA Drug Safety Update (Aug 2015) - Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone

Sofosbuvir (1)▼
BNF | BNFC | SPC

NICE TA361 - Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal)

Ledipasvir-Sofosbuvir▼
BNF | BNFC | SPC

400mg / 90mg film coated tablets

Commissioner: NHS England - NICE TA363

Daclatasvir▼
BNF | BNFC | SPC

30mg and 60mg tablets

Commissioner: NHS England - NICE TA364

Ombitasvir-Paritaprevir-Ritonavir▼
BNF | BNFC | SPC

Tablets containing ombitasvir 12.5mg, paritaprevir 75mg
& ritonavir 50mg

Commissioner: NHS England - NICE TA365

Elbasvir-Grazoprevir▼
BNF | BNFC | SPC

Each film-coated tablet contains 50 mg elbasvir and 100 mg grazoprevir.

Commissioner: NHS England - NICE TA413

 

Sofosbuvir-Velpatasvir
BNF | BNFC | SPC

Epclusa(R) 400 mg/100 mg film-coated tablets

 Commissioner: NHS England - NICE TA430

Oseltamivir
BNF | BNFC | SPC

30mg, 45mg & 75mg capsules
6mg in 1ml (30mg in 5ml) oral suspension

NICE TA158

Zanamivir
BNF | BNFC | SPC

5mg/blister dry powder for inhalation via Diskhaler®

NICE TA158, NICE TA168

For use if there is resistance to oseltamivir

Ribavirin
BNF | BNFC | SPC

6g in 300ml inhalation - for use on specialist microbiological advice 
200mg tablets and capsules - approved for chronic hepatitis in line with NICE, see peginterferon alfa 2a/2b AND approved treatment for children and young people with chronic hepatitis C,

Palivizumab
BNF | BNFC | SPC

50mg & 100mg injections

Commissioner: NHS England – JCVI Guidelines PHE Specification

Drugs for malaria prophylaxis are not prescribable on the NHS. Prescription only medicines for malaria prophylaxis should be prescribed privately. The GP may also make a charge for the consultation and supplying the prescription if they wish.
Some medicines for malaria prophylaxis are available for purchase over the counter at community pharmacies. Community pharmacies also have access to up to date advice regarding prophylactic regimes and can advise travellers accordingly.

Chloroquine
BNF | BNFC | SPC

200mg tablets (= 150mg chloroquine base)
68mg in 5ml syrup (= 50mg in 5ml chloroquine)

Mefloquine
BNF | BNFC | SPC

250mg tablets

Primaquine
BNF | BNFC | SPC

7.5mg tablets

Proguanil
BNF | BNFC | SPC

100mg tablets

Pyrimethamine
BNF | BNFC | SPC

25mg tablets

Malarone
BNF | BNFC | SPC

Tablets (100mg proguanil & 250mg atovaquone)
Paediatric tablets (proguanil 25mg & atovaquone 62.5mg)

Quinine
BNF | BNFC | SPC

Quinine sulphate 200mg tablets

Co-trimoxazole
BNF | BNFC | SPC

- see section 5.1.8

Atovaquone
BNF | BNFC | SPC

750mg in 5ml sugar-free suspension

Approved for use in patients intolerant of co-trimoxazole.

Mebendazole
BNF | BNFC | SPC

100mg tablets
100mg in 5ml suspension

Pripsen
BNF | BNFC | SPC

Sachets - containing piperazine phosphate 4g & sennosides 15.3mg/sachet

Levamisole
BNF | BNFC | SPC

50mg tabletsu

For roundworm infections.